Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares (2023 - 2025)

Historic Preferred Shares for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $146.4 million.

  • Spyre Therapeutics' Preferred Shares changed 0.0% to $146.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $146.4 million for FY2024, which is 2082.01% down from last year.
  • As of Q3 2025, Spyre Therapeutics' Preferred Shares stood at $146.4 million, which was down 0.0% from $146.4 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Preferred Shares ranged from a high of $184.9 million in Q4 2023 and a low of $146.4 million during Q2 2024
  • Over the past 3 years, Spyre Therapeutics' median Preferred Shares value was $146.4 million (recorded in 2024), while the average stood at $156.1 million.
  • Per our database at Business Quant, Spyre Therapeutics' Preferred Shares tumbled by 2082.01% in 2024 and then changed by 0.0% in 2025.
  • Spyre Therapeutics' Preferred Shares (Quarter) stood at $184.9 million in 2023, then fell by 20.82% to $146.4 million in 2024, then changed by 0.0% to $146.4 million in 2025.
  • Its Preferred Shares stands at $146.4 million for Q3 2025, versus $146.4 million for Q2 2025 and $146.4 million for Q1 2025.